Development and validation of RP-HPLC and RP-UPLC methods for quantification of erythropoietin formulated with human serum albumin

Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics

In this review, we focus on providing basics and examples for each component of the protein therapeutic specifications to interested pharmacists and biopharmaceutical scientists with a goal to strengthen understanding in regulatory science and compliance. Pharmaceutical specifications comprise a list of important quality attributes for testing, references to use for test procedures, and appropriate acceptance criteria for the tests, and they are set up to ensure that when a drug product is administered to a patient, its intended therapeutic benefits and safety can be rendered appropriately. Conformance of drug substance or drug product to the specifications is achieved by testing an article according to the listed tests and analytical methods and obtaining test results that meet the acceptance criteria. Quality attributes are chosen to be tested based on their quality risk, and consideration should be given to the merit of the analytical methods which are associated with the acceptance criteria of the specifications. Acceptance criteria are set forth primarily based on efficacy and safety profiles, with an increasing attention noted for patient-centric specifications. Discussed in this work are related guidelines that support the biopharmaceutical specification setting, how to set the acceptance criteria, and examples of the quality attributes and the analytical methods from 60 articles and 23 pharmacopeial monographs. Outlooks are also explored on process analytical technologies and other orthogonal tools which are on-trend in biopharmaceutical characterization and quality control.

Comprehensive Glycosylation Characterization of Recombinant Human Erythropoietin by Electron-Activated Dissociation Mass Spectrometry

Recombinant human erythropoietin (rhEPO) is a glycoprotein that acts as the main hormone involved in regulating red blood cell production to treat anemia caused by chronic kidney disease or chemotherapy, which has three N-glycosylation sites and one O-glycosylation site. It contains a variety of different glycosylation modifications, such as sialyation, O-acetylation on sialic acids, etc., which causes a big challenge for the glycosylation analysis of rhEPO. In this study, a liquid chromatography-mass spectrometry (LC-MS) method combined with electron-activated dissociation (EAD) technology was used in qualitative and quantitative characterization of rhEPO N-glycosylation and O-glycosylation in just one injection. The usage of EAD not only generated abundant MS/MS fragment ions of glycopeptides and improved the MS/MS sequence coverage but also preserved the glycan structures in the MS/MS fragment ions and the integrity of the glycosidic bond between the glycans and peptides. Three N-glycosylation sites (N24, N38, and N83) and one O-glycosylation site (S126) of rhEPO samples were successfully identified. Among them, the glycosylation ratios of N24, N38, and N83 sites were 82.7%, 100%, and 100% respectively, and 15, 10, and 12 different N-glycans could be identified at the glycopeptide level. The total average number of sialic acids, N-hydroxyacetylneuraminoic acid, and O-acetylation on sialic acid were 7.28, 4.21, and 0.66 at the intact protein level, respectively. For O-glycosylation site S126, O-glycosylation ratios analyzed at the intact protein level and the glycopeptide level were 80.2% and 80.3%, respectively, and two O-glycans were identified, including Core1_S1 and Core1_S2. This study also compared the difference of the glycans and their relative contents in batch-to-batch rhEPO samples. The results proved that the workflow using EAD fragmentation in LC-MS method could be effectively applied for characterizing the glycosylation analysis of rhEPO samples and batch-to-batch consistency analysis, which would help to reasonably guide the optimization of rhEPO production process.

UPLC Technique in Pharmacy—An Important Tool of the Modern Analyst

In recent years, ultra-efficient liquid chromatography (UPLC) has gained particular popularity due to the possibility of faster separation of small molecules. This technique, used to separate the ingredients present in multi-component mixtures, has found application in many fields, such as chemistry, pharmacy, food, and biochemistry. It is an important tool in both research and production. UPLC created new possibilities for analytical separation without reducing the quality of the obtained results. This technique is therefore a milestone in liquid chromatography. Thanks to the increased resolution, new analytical procedures, in many cases, based on existing methods, are being developed, eliminating the need for re-analysis. Researchers are trying to modify and transfer the analytical conditions from the commonly used HPLC method to UPLC. This topic may be of strategic importance in the analysis of medicinal substances. The information contained in this manuscript indicates the importance of the UPLC technique in drug analysis. The information gathered highlights the importance of selecting the appropriate drug control tools. We focused on drugs commonly used in medicine that belong to various pharmacological groups. Rational prescribing based on clinical pharmacology is essential if the right drug is to be administered to the right patient at the right time. The presented data is to assist the analyst in the field of broadly understood quality control, which is very important, especially for human health and treatment. This manuscript shows that the UPLC technique is now an increasingly used tool for assessing the quality of drugs and determining the identity and content of active substances. It also allows the monitoring of active substances and finished products during their processing and storage.

Application of Supervised and Unsupervised Learning Approaches for Mapping Storage Conditions of Biopharmaceutical Product-A Case Study of Human Serum Albumin

The stability of biopharmaceutical therapeutics over the storage period/shelf life has been a challenging concern for manufacturers. A noble strategy for mapping best and suitable storage conditions for recombinant human serum albumin (rHSA) in laboratory mixture was optimized using chromatographic data as per principal component analysis (PCA), and similarity was defined using hierarchical cluster analysis. In contrast, separability was defined using linear discriminant analysis (LDA) models. The quantitation was performed for rHSA peak (analyte of interest) and its degraded products, i.e., dimer, trimer, agglomerates and other degradation products. The chromatographic variables were calculated using validated stability-indicating assay method. The chromatographic data mapping was done for the above-mentioned peaks over three months at different temperatures, i.e., 20°C, 5-8°C and at room temperature (25°C). The PCA had figured out the ungrouped variable, whereas supervised mapping was done using LDA. As an outcome result of LDA, about 60% of data were correctly classified with the highest sensitivity for 25°C (Aq), 25°C and 5-8°C (Aq with 5% glucose as a stabilizer), whereas the highest specificity was observed for samples stored at 5-8°C (Aq with 5% glucose as a stabilizer).

Determination of the pharmaceuticals-nano/microplastics in aquatic systems by analytical and instrumental methods

Pharmaceutical residues and nanoplastic and microplastic particles as emerging pollutants in the aquatic environment are a subject of increasing concern in terms of the effect on water sources and marine organisms. There is lack of information about pharmaceutical-nanoplastic and pharmaceutical-microplastic mixtures. The present study aimed to investigate the fate and effect of pharmaceutical residues and nanoplastic and microplastic particles, the results of combinations of pharmaceutical residues with nanoplastic and microplastic particles, and toxic effects of pharmaceutical residues and nanoplastic and microplastic particles. Moreover, the objective was also to introduce analytical methods for pharmaceuticals, along with instrumental techniques for nanoplastic and microplastic particles in aquatic environments and organisms. PhAC alone can affect marine environments and aquatic organisms. When pharmaceutical residues combine with nanoplastic and microplastic particles, the rate of toxicity increases, and the result of this phenomenon constitutes this kind of pollutant in wastewater. Hence, the rate of mortality in organisms enhances. This study aimed to investigate the effect of pharmaceuticals residues and nanoplastic and microplastic particles, and a mixture of pharmaceutical residues and nanoplastic and microplastic particles in aquatic biota. Another object was survey methods for recognizing pharmaceutical residues and nanoplastic and microplastic particles. The findings show that pharmaceutical residues in organisms caused cell structure damage, inflammatory response, and nerve cell apoptosis. This study aimed to investigate the effect of microplastic particles in the human food chain and their impact on human health. Moreover, this review aims to present an innovative methodology based on comprehensive analytical techniques used to determine and identify pharmaceuticals adsorbed on nano- and microplastics in aquatic ecosystems. Finally, this review addresses the knowledge gaps and provides insights into future research strategies to better understand their interactions.

Preparation and characterization of 96-well microplates coated with molecularly imprinted polymer for determination and biosimilarity assessment of recombinant human erythropoietin

Synthesis and applications of molecularly imprinted polymers (MIP) are rapidly growing. In this study, a biomimetic MIP was prepared through silanes polymerization on the surface of 96-well microplates using recombinant human erythropoietin-alfa (rhEPO) as a template molecule. The rhEPO was immobilized onto the plate surface using bi-functional cross-linker and a thin imprinted layer following sol-gel procedure was constructed. After template extraction, uniform three-dimensional cavities compatible with the configuration of rhEPO were obtained. The rhEPO-MIP preparation was optimized using 2-level factorial design and response surface design where polymerization time and interactions between the different variable were found to be the most significant factors. Size-exclusion chromatography (SEC) was used to monitor the stability of the rhEPO under the investigated polymerization conditions. Determination of rhEPO using the MIP microplate showed good dynamic response fitting to the 4 PL regression model (0.9962) over a concentration range of 10.00 - 100.00 ng mL^-1. Adsorption of rhEPO onto MIP followed the Langmuir isotherm model (r = 0.9957, χ² =0.02786) with pseudo-second-order kinetics (r = 0.9984). The surface of the rhEPO-MIP was characterized using scanning electron microscopy (SEM) while step-by-step surface modification was tracked using Fourier transform infrared (FTIR) spectroscopy. The rhEPO-MIP was able to distinguish between the rhEPO-alfa template and modified rhEPO molecules; rhEPO-beta, hyperglycosylated and pegylated forms (imprinting factors < 2) and in the commonly used formulation additive human serum albumin (HSA) (R% = 113.96 -95.22%). The rhEPO-MIP was applied to compare the receptor-binding pattern to rhEPO and its biosimilars / structural analogues. The results were cross-validated using the conventional assay protocol (RP-HPLC and ELISA) and an acceptable correlation was observed with RP-HPLC (maximum deviation is 7.78%). This work confirmed the applicability of rhEPO-MIP with its unique binding features for batch release, stability and biosimilarity assessment as well as subsequent evaluation of batch-to-batch consistency during bioproduction of target analytes.

Recent Advances on Drug Analyses Using Ultra Performance Liquid Chromatographic Techniques and their Application to the Biological Samples

Introduction:

Ultra-Performance Liquid Chromatographic (UPLC) method enables analyst to establish an analysis at higher pressure than High Performance Liquid Chromatographic (HPLC) method towards liquid chromatographic methods. UPLC method provides the opportunity to study a higher pressure compared to HPLC, and therefore smaller column in terms of particle size and internal diameter are generally used in drug analysis. The UPLC method has attracted gradually due to its advantages such as short analysis time, the small amount of waste reagents and the significant savings in the cost of their destruction process. In this review, the recent selected studies related to the UPLC method and its method validation are summarized. The drug analyses and the results of the studies which were investigated by UPLC method, with certain parameters from literature are presented.

Background:

Quantitative determination of drug active substances by High-Performance Liquid Chromatography (HPLC) from Liquid Chromatography (LC) methods has been carried out since the 1970's with the use of standard analytical LC methods. In today's conditions, rapid and very fast even ultra-fast, flow rates are achieved compared to conventional HPLC due to shortening analysis times, increasing method efficiency and resolution, reducing sample volume (and hence injection volume), reducing waste mobile phase. Using smaller particles, the speed and peak capacity are expanding to new limit and this technology is named as Ultra Performance Liquid Chromatography. In recent years, as a general trend in liquid chromatography, ultra-performance liquid chromatography has taken the place of HPLC methods. The time of analysis was for several minutes, now with a total analysis time of around 1-2 minutes. The benefits of transferring HPLC to UPLC are much better understood when considering the thousands of analyzes performed for each active substance, in order to reduce the cost of analytical laboratories where relevant analysis of drug active substances are performed without lowering the cost of research and development activities.

Methods:

The German Chemist Friedrich Ferdinand Runge, proposed the use of reactive impregnated filter paper for the identification of dyestuffs in 1855 and at that time the first chromatographic method in which a liquid mobile phase was used, was reviewed. Christian Friedrich Chönbein, who reported that the substances were dragged at different speeds in the filter paper due to capillary effect, was followed by the Russian botanist Mikhail S. Tswet, who planted studies on color pigment in 1906. Tswet observes the color separations of many plant pigments, such as chlorophyll and xanthophyll when he passes the plant pigment extract isolated from plant through the powder CaCO3 that he filled in the glass column. This method based on color separation gives the name of "chromatographie" chromatography by using the words "chroma" meaning "Latin" and "graphein" meaning writing.

Results and Conclusion:

Because the UPLC method can be run smoothly at higher pressures than the HPLC method, it offers the possibility of analyzing using much smaller column sizes and column diameters. Moreover, UPLC method has advantages, such as short analysis time, the small amount of waste reagents and the significant savings in the cost of their destruction process. The use of the UPLC method especially analyses in biological samples such as human plasma, brain sample, rat plasma, etc. increasingly time-consuming due to the fact that the analysis time is very short compared to the HPLC, because of the small amount of waste analytes and the considerable savings in their cost.

Principle, Instrumentation, and Applications of UPLC: A Novel Technique of Liquid Chromatography

The key focus of the pharmaceutical or chemical industries is to reduce the cost involved in the development of new drugs and to improve the selectivity, sensitivity, and resolution for their detection. The purpose can now be solved by the separation method called UPLC which is the modified HPLC method comprising high pressure and small sized particles (less than 2 µm) used in the column, so the length of the column decreases leading to time saving and reduction in the consumption of solvent. The underlying principle of UPLC is based on van Deemter statement which describes the connection between linear velocity with plate height. UPLC contributes to the improvement of the three areas: speed, resolution, and sensitivity. This is a new advanced category of the HPLC which has the same basic principle and methodology with improved chromatographic performance. This review is an effort to compile the principle, instrumentation, and applications of UPLC.

Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis

A variant peak was detected in the analysis of RP-HPLC of rHu-EPO, which has about 7% relative content. Fractions of the main and the variant peaks were pooled separately and further analyzed to identify the molecular structure of the variant peak. Total mass analysis for each peak fraction using ESI-TOF MS shows differences in molecular mass. The fraction of the main peak tends to result in higher molecular masses than the fraction of the variant. The detected masses for the variant are about 600-1000 Da smaller than those for the main peak. Peptide mapping analysis for each peak fraction using Asp-N and Glu-C shows differences in O-glycopeptide profiles at Ser126. The O-glycopeptides were not detected in the fraction of the variant. It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.

UHPLC: The Greening Face of Liquid Chromatography

Pharmaceutical analysis based on chromatographic separation is an important part of studies aimed at developing routine quality analysis of drugs. High-performance liquid chromatography (HPLC) is one of the main analytical techniques recommended for drug analysis. Although it meets many criteria vital for analysis, it is time-consuming and uses a relatively high amount of organic solvents compared to other analytical techniques. Recently, Ultra-high-performance liquid chromatography (UHPLC) has been frequently proposed as an alternative to HPLC, which means introducing an environment-friendly approach to drug analysis achieved by reducing the consumption of solvents. It also offers greater chromatographic resolution and higher sensitivity as well as requiring less time due to faster analysis. This review focuses on the basics of UHPLC, compares that technique with HPLC and discusses the possibilities of applying UHPLC for the analysis of different pharmaceuticals and biopharmaceuticals.